Price$5.54-6.46 (-53.83%)
2026-03-042026-06-05
News · 26 weeks45+18%
2025-12-142026-06-07
Mix3690d
- Insider16(44%)
- SEC Filings12(33%)
- Earnings4(11%)
- Other2(6%)
- Analyst2(6%)
Latest news
25 items- INSIDERDirector Hammer Todd B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERDirector Ellis Thomas B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERPrincipal Accounting Officer Wong Kendra was granted 13,066 shares, increasing direct ownership by 30% to 56,481 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERChief Operating Officer Connaughton Alan B. was granted 34,843 shares, increasing direct ownership by 10% to 389,173 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERChief Executive Officer Curtis Nicholas T was granted 130,662 shares, increasing direct ownership by 13% to 1,122,758 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERDirector Weisner Aimee S was granted 17,421 shares, increasing direct ownership by 19% to 110,368 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERDirector O'Farrell Elizabeth G. was granted 17,421 shares, increasing direct ownership by 35% to 67,368 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERDirector Winer Gary M was granted 17,421 shares, increasing direct ownership by 20% to 105,635 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERDirector Lindstrom Richard L Md was granted 17,421 shares, increasing direct ownership by 7% to 263,831 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERDirector Link William J Phd was granted 17,421 shares, increasing direct ownership by 3% to 568,062 units (SEC Form 4)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERSEC Form 3 filed by new insider Rossi Michael A.3 - LENSAR, Inc. (0001320350) (Issuer)
- SECSEC Form S-8 filed by LENSAR Inc.S-8 - LENSAR, Inc. (0001320350) (Filer)
- SECLENSAR Inc. filed SEC Form 8-K: Leadership Update, Shareholder Director Nominations, Other Events8-K - LENSAR, Inc. (0001320350) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by LENSAR Inc.SCHEDULE 13G/A - LENSAR, Inc. (0001320350) (Subject)
- SECSEC Form 144 filed by LENSAR Inc.144 - LENSAR, Inc. (0001320350) (Subject)
- INSIDERChief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,739 shares, decreasing direct ownership by 0.77% to 354,330 units (SEC Form 4) (tax liability)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERChief Executive Officer Curtis Nicholas T disposed of 0 shares (SEC Form 4) (for withholding tax)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERChief Financial Officer Staab Thomas R Ii covered exercise/tax liability with 1,350 shares, decreasing direct ownership by 0.77% to 174,609 units (SEC Form 4) (tax withholding)4 - LENSAR, Inc. (0001320350) (Issuer)
- INSIDERPrincipal Accounting Officer Wong Kendra covered exercise/tax liability with 864 shares, decreasing direct ownership by 2% to 43,415 units (SEC Form 4) (for tax liability)4 - LENSAR, Inc. (0001320350) (Issuer)
- SECSEC Form 10-Q filed by LENSAR Inc.10-Q - LENSAR, Inc. (0001320350) (Filer)
- SECLENSAR Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LENSAR, Inc. (0001320350) (Filer)
- PRLENSAR® Reports First Quarter 2026 Results and Provides Business Update7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser Installed Base Climbs to 440 Systems, Driven by 39% Growth in ALLY Placements ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2026 and provided an update on key operational initiatives. "Our first quarter total revenue and related system placement results decre
- SECAmendment: SEC Form 10-K/A filed by LENSAR Inc.10-K/A - LENSAR, Inc. (0001320350) (Filer)
- PRLENSAR® to Report First Quarter 2026 Results on May 8, 2026ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026. LENSAR's management will host a conference call and webcast at 8:30 am ET on Friday, May 8, 2026 to discuss the results, recent corporate and operational highlights and provide an update on key strategic initiatives. To participate by telephone, please use this registration link. All participants must use the link to complete the online registra
- SECLENSAR Inc. filed SEC Form 8-K: Leadership Update8-K - LENSAR, Inc. (0001320350) (Filer)
LNSR FAQ
6 questionsWhat does LENSAR Inc. do?
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.Where does LNSR stock trade?
LENSAR Inc. (LNSR) is listed on NASDAQ.What sector and industry is LNSR in?
LENSAR Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about LNSR?
LENSAR Inc. has had 3 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $1000.00 price target on 2026-04-01. Recent price targets range from $1000.00 to $1500.00.What companies are similar to LNSR?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare LNSR side-by-side with any of them on Quantisnow.How can I track LNSR on Quantisnow?
Quantisnow aggregates LENSAR Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LNSR to receive live email and push alerts on every new disclosure.